BOBULSKY SUSAN sold $32K of ADPT

BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold 1,195 shares of Adaptive Biotechnologies Corp (ADPT) at $27.00 on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BOBULSKY SUSAN
Published Sep 17, 2026, 10:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The sale is modest and pre‑arranged, suggesting no immediate market impact.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming regulatory or clinical trial news not disclosed in the filing.

Relevance 2/10Novelty 3/10Timing: filed Sep 17 2026 (post‑market)

Background

Form 4 filing reports insider transactions required by SEC; provides transparency on officer holdings.

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

Chief Commercial Officer sold 1,195 shares for $32,265 via a 10b5-1 plan on Sep 15, 2026

Expected impact

minimal impact; price likely unchanged

Evidence & confidence

The transaction amount is small relative to total holdings and market cap; such sales are routine and rarely affect price.

Market effects

None; insider sale does not affect biotech sector outlook.

None; limited to Adaptive Biotechnologies shareholders.

None; isolated event.

Counterpoint

If the insider is reducing exposure, it could signal concerns about near‑term prospects.

Key entities

  • Adaptive Biotechnologies Corp

    US‑listed biotech firm (ticker ADPT).

  • Susan Bobulsky

    Chief Commercial Officer, MRD at Adaptive Biotechnologies.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.